January 25, 2015 5:31 AM ET


Company Overview of North American Vaccine

Company Overview

As of June 2000, North American Vaccine, Inc. was acquired by Baxter International Inc. North American Vaccine, Inc., prior to the acquisition, was engaged in the research, development, manufacture, and sale of vaccines for the prevention of infectious diseases. The company had three licensed products that contained its acellular pertussis vaccine, including Certiva®, its combined diphtheria, tetanus, and acellular pertussis vaccine for infants and children, as well as 12 other products in various stages of development to prevent meningococcal, streptococcal, pneumococcal, E. coli, and HAEMOPHILUS INFLUENZAE type b infections.

10150 Old Columbia Road

Columbia, MD 21046

United States

267 Employees



Key Executives for North American Vaccine

North American Vaccine does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Curative Biosciences, Inc. United States
Girindus America Inc. United States
Arteriocyte, Inc. United States
Applied Molecular Evolution, Inc. United States
TELA Bio, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact North American Vaccine, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.